Staphylococcus and Neisseria Tablets in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. - Trial NCT05543343
Access comprehensive clinical trial information for NCT05543343 through Pure Global AI's free database. This phase not specified trial is sponsored by Qu Yiqing and is currently Recruiting. The study focuses on Pulmonary Disease, Chronic Obstructive. Target enrollment is 495 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
High dose or normal dose staphylococcus albicans
Interventional
drug
Sponsor & Location
Qu Yiqing
Qilu Hospital of Shandong University
Timeline & Enrollment
N/A
Jan 05, 2022
Aug 01, 2023
Primary Outcome
Number of acute exacerbations of chronic obstructive pulmonary disease in 1 year
Summary
It is planned to enroll 495 acute exacerbation of chronic obstructive pulmonary disease
 patients, and they will be randomly assigned to the high-dose test group, normal dose test
 group or control group at a ratio of 1:1:1, with 165 patients in each group. The course of
 treatment is 90 days, and the total follow-up time is one year. The purpose of the study is
 to evaluate the effectiveness and safety of different doses of bacterial lysates
 (Staphylococcus and Neisseria Tablets) in the treatment of acute exacerbation of chronic
 obstructive pulmonary disease.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05543343
Non-Device Trial